This study is a multicenter, randomized, prospective Phase II clinical trial designed to compare the effectiveness of two treatment approaches for patients with acute monocytic leukemia.
Voluntary participation with written informed consent signed by the participant or a legal guardian; willingness to comply with all study procedures.
Age 14 to 60 years at screening, no gender restriction.
Diagnosis of acute monocytic leukemia according to the 2016 WHO classification, excluding acute promyelocytic leukemia.
No history of severe allergic reactions.
Known hypersensitivity or contraindication to any study drug.
Pregnancy or lactation.
Active infection.
Long-term smoking or alcohol abuse that may interfere with study outcome evaluation.
Chinese PLA General Hospital
Lead sponsor
Air Force Medical Center of PLA
Collaborator
PLA Strategic Support Force's Characteristic Medical Center
Collaborator